RXST News & Events

Consensus $129.24M. The company said that the FY26 revenue view is inclusive of RxSight sales and revenue recognized from the RxSight Alcon Strategic Collaboration, comprised of: Sales of $110M-$120M, below previous guidance of $120M-$135M; Collaboration Agreement revenue of $30M-$40M, subject to the terms and conditions described in the Current Report on Form 8-K filed with the Securities and Exchange Commission on or about the date hereof; Gross margin of 73% to 75%, above previous guidance of 70% to 72%; and Operating expense at the high-end of $150M-$160M, in line with previous guidance.

Yesterday, the company said that the preliminary revenue view includes $5M-$7M in revenue recognized from the RxSight Alcon Strategic Collaboration, with the specific amount expected to be reported with the company's financial results for the second quarter of 2026 in August 2026. RxSight also expects sales of roughly $27M, including the sale of 24,917 Light Adjustable Lens units and 11 Light Delivery Devices units; 1 rental unit placed. "While we faced meaningful commercial headwinds in Q2, including from more widespread competitive trialing, the unique ability of RxSight's Light Adjustable Technology to customize visual outcomes continued to deliver significant clinical benefits to thousands of patients around the world," said Dr. Ron Kurtz, Chief Executive Officer and President of RxSight. "To position the company for deeper penetration of current, next-generation, and collaboration products, we are accelerating investments in our LAL sales force and commercial capabilities, while maintaining a disciplined approach to overall spending. By leveraging our differentiated technology, large customer base, strong balance sheet and exciting pipeline, we believe RxSight is well positioned to drive both high-margin implant sales and future royalty income, thereby empowering doctors to deliver the industry's premier outcomes for even more of their patients."